^
Association details:
| Biomarker: | BRAF L597K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRAF L597K mutation: an opportunity to treat
Published date:
01/15/2021
Excerpt:
In November 2017, next generation sequencing genomic profiling disclosed a rare L597K-BRAF mutation and vemurafenib plus cobimetinib therapy was initiated in January 2018. Seven days after treatment start, a remarkable clinical improvement was observed...this is the first case reporting response to combined iBRAF/iMEK therapy in a patient with metastatic melanoma harboring L597K mutation.
